1 / 7

Availability of Medicines

Availability of Medicines. Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy. Evidence on Medicines Availability. *Cameron et al, Lancet, 2009. MeTA facility surveys Supply side assessment Average public sector generic availability 30%-55%*

nara
Download Presentation

Availability of Medicines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy

  2. Evidence on Medicines Availability *Cameron et al, Lancet, 2009 • MeTA facility surveys • Supply side assessment • Average public sector generic availability 30%-55%* • Generics in public facilities < generics in private facilities • Generics for chronic conditions < generics for acute conditions • MeTA household surveys • Add demand side perspective • Consumer perceptions seem consistent with facility data • Public facilities < private facilities • Chronic disease medicines < acute condition medicines • Lack of public sector availability seems to impact adherence • Differently for poor, near-poor, less poor

  3. Key Observations Multi-pronged, multi-level, multi-stakeholder approaches essential to improving availability • Appropriate, high-quality, affordable medicines must be available for health care to improve health • Availability is complex, multi-factorial • International and national regulations • Manufacturing • Forecasting to match clinical need, guideline-based treatment, & drug lists • Procurement, distribution, warehousing logistics • Financing within systems, for patients • Incentives for manufacturer, purchasers, prescribers, dispensers • Education, training, awareness generation of all stakeholders (logistics, cost, appropriate prescribing, dispensing, use) • Fragmented, decentralised health care systems challenge availability further

  4. Sample Interventions in MeTA Countries • Regulation • Generic laws (Philippines) • Legislation for price reductions to increase availability for middle class (Philippines) • “New law on medicines” (Peru) • Pooled procurement • Negotiating power of volume for price, quality, availability, geographic distribution (Jordan: Joint Procurement Department) • Centralised procurement with public tender and accountability for timely, decentralised distribution (Peru) • Procurement from pre-qualified suppliers (Zambia) • Financing • Separate drug budgets in facilities (Ghana: NHIA reimbursement) • Basic outpatient drug package for chronic conditions & forecasting budget needs using claims data (Kyrgyzstan) • Information generation & disclosure • Civil society & media engagement on stock-outs => Drug Monitoring Unit (Uganda) • Availability discussion in review of national medicines policy (Zambia)

  5. Sample Policy Suggestions • Pharmaceutical management • Developing & implementing formulary process related to STG (Jordan) • National formulary system implementation (Philippines) • Financing • Differentiate policy interventions targeting poor, near-poor • Access to care & free, high quality, appropriate drugs needed for the poor • Incentivise manufacturing, procurement, availability, prescribing, dispensing of appropriate medicines (according to formularies) • Insure flow of funds (Ghana: NHIA reimbursement times) • Implement policies to incentivize appropriate use of generic first-line products with patient cost-sharing for non-poor where appropriate (Kyrgyzstan) • Information generation and disclosure • Routine online data bases of price and availability (Peru, Uganda) • Creation of regional MeTA offices (Peru) • Continued consideration of availability (and other MeTA core principles) in Parliament (Zambia)

  6. Information Generationand Dissemination • Publish processes and outcomes of MeTA pilot phase • WHO Essential Medicines Monitor: http://www.who.int/medicines/publications/monitor/en/index.html • WHO Medicines Documentation Centre: http://apps.who.int/medicinedocs/en/ • ICIUM2011: www.icium2011.org • Build evaluation and routine monitoring of impacts into policy change • Data • Tools • Indicators • Evaluation design/methods • Analysis • Dissemination • Share experiences and results globally

  7. Thank you Anita Wagner Email: awagner@hms.harvard.edu Skype: anita.wagner International MeTA Secretariat: admin@metasecretariat.org MeTA: www.MedicinesTransparency.or

More Related